Clinical Trials
9 trialsNCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT05614739 2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1 Recruiting
NCT07087860 2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT06349668 2026-02-05
SMILe
University Hospital, Linkoeping
Phase 3 Recruiting
NCT07125547 2025-08-15
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06983210 2025-08-14
GRAPE
Nagoya University
Phase 2 Recruiting
NCT05756569 2025-07-28
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
Phase 2 Recruiting
NCT06652022 2024-10-22
Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs
Peking University First Hospital
Phase NA Recruiting